CROSSJECT announces initiation of coverage of its stock by Portzamparc (BNP Paribas Group)

Core Viewpoint - CROSSJECT, a specialty pharmaceutical company, has announced the initiation of stock coverage by Portzamparc (BNP Paribas Group) with a "Strong Buy" recommendation and a target price of €4.50 [1]. Company Overview - CROSSJECT is developing emergency medicines utilizing its ZENEO® needle-free auto-injector technology, which allows for easy and instant delivery of drugs [2]. - The company is in advanced regulatory development for ZEPIZURE®, an injectable treatment for epileptic seizures, supported by a $60 million contract with BARDA [2][3]. - Other products in development include solutions for allergic shocks, adrenal insufficiencies, and various emergency indications [2].